- Home
- LEU vs ANAB Comparison
LEU vs ANAB Comparison
Compare LEU & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LEU
- ANAB
- Stock Information
- Founded
- LEU 1998
- ANAB 2005
- Country
- LEU United States
- ANAB United States
- Employees
- LEU N/A
- ANAB N/A
- Industry
- LEU Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- LEU Industrials
- ANAB Health Care
- Exchange
- LEU Nasdaq
- ANAB Nasdaq
- Market Cap
- LEU 3.1B
- ANAB 621.1M
- IPO Year
- LEU 1998
- ANAB 2017
- Fundamental
- Price
- LEU $201.89
- ANAB $26.55
- Analyst Decision
- LEU Strong Buy
- ANAB Buy
- Analyst Count
- LEU 10
- ANAB 10
- Target Price
- LEU $171.67
- ANAB $44.25
- AVG Volume (30 Days)
- LEU 1.4M
- ANAB 499.6K
- Earning Date
- LEU 08-05-2025
- ANAB 08-04-2025
- Dividend Yield
- LEU N/A
- ANAB N/A
- EPS Growth
- LEU 40.85
- ANAB N/A
- EPS
- LEU 6.39
- ANAB N/A
- Revenue
- LEU $471,400,000.00
- ANAB $111,872,000.00
- Revenue This Year
- LEU $3.22
- ANAB N/A
- Revenue Next Year
- LEU $9.91
- ANAB $24.39
- P/E Ratio
- LEU $32.28
- ANAB N/A
- Revenue Growth
- LEU 58.72
- ANAB 387.20
- 52 Week Low
- LEU $33.51
- ANAB $12.21
- 52 Week High
- LEU $211.31
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- LEU 69.05
- ANAB 70.24
- Support Level
- LEU $167.26
- ANAB $23.10
- Resistance Level
- LEU $188.50
- ANAB $26.17
- Average True Range (ATR)
- LEU 16.92
- ANAB 1.33
- MACD
- LEU -0.79
- ANAB 0.27
- Stochastic Oscillator
- LEU 91.87
- ANAB 100.00
About LEU Centrus Energy Corp.
Centrus Energy Corp is engaged in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment has two components which include the sale of separative work units and uranium. The Technical Solutions segment provides engineering, design, and manufacturing services to government and private sector customers. The majority of the firm's revenue is derived from the LEU segment. It has a business presence in the U.S. and other countries, of which prime revenue is generated in the U.S.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).